TEL AVIV, Israel, Nov.
1, 2018 /PRNewswire/ -- Cellect Biotechnology Ltd. (NASDAQ:
APOP) , a developer of a novel stem cell production technology,
announced today its CEO Dr. Shai
Yarkoni will present at the 24th Annual Bio
Europe Conference which is being held in Copenhagen, Denmark from November 5-7, 2018. Dr. Yarkoni will present as
part of the Cell and Gene Therapies track on Tuesday, November 6 at 10:15 am.
The 24th Annual BIO-Europe conference is Europe's largest partnering conference serving
the global biotechnology industry. This year´s BIO-Europe
partnering event is expected to draw over 4,000 industry attendees
from over 60 countries, representing more than 2,100 companies for
three days of high level networking.
"Our ApoGraft™ technology is designed to enable stem cell
companies around the world to manufacture and perform safer and
more cost effective stem cell-based therapeutics. We believe our
technology represents a breakthrough in meeting the rapidly growing
demand for stem cells as a raw material. We look forward to meeting
with other stem cell leaders with a view towards collaboration and
commercialization," stated Cellect CEO Dr. Shai Yarkoni.
About Cellect Biotechnology Ltd.
Cellect Biotechnology (NASDAQ: APOP) has developed a
breakthrough technology for the selection of stem cells from any
given tissue that aims to improve a variety of stem cell-based
therapies.
The Company's technology is expected to provide research,
hospitals and pharma companies with the tools to rapidly isolate
stem cells in quantity and quality allowing stem cell-based
treatments and procedures in a wide variety of applications in
regenerative medicine. The Company's current clinical trial is
aimed at bone marrow transplantations in cancer treatment.
Forward Looking Statements
This press release contains forward-looking statements about the
Company's expectations, beliefs and intentions. Forward-looking
statements can be identified by the use of forward-looking words
such as "believe", "expect", "intend", "plan", "may", "should",
"could", "might", "seek", "target", "will", "project", "forecast",
"continue" or "anticipate" or their negatives or variations of
these words or other comparable words or by the fact that these
statements do not relate strictly to historical matters. These
forward-looking statements and their implications are based on the
current expectations of the management of the Company only and are
subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. In addition, historical results or
conclusions from scientific research and clinical studies do not
guarantee that future results would suggest similar conclusions or
that historical results referred to herein would be interpreted
similarly in light of additional research or otherwise. The
following factors, among others, could cause actual results to
differ materially from those described in the forward-looking
statements: the Company's history of losses and needs for
additional capital to fund its operations and its inability to
obtain additional capital on acceptable terms, or at all; the
Company's ability to continue as a going concern; uncertainties of
cash flows and inability to meet working capital needs; the
Company's ability to obtain regulatory approvals; the Company's
ability to obtain favorable pre-clinical and clinical trial
results; the Company's technology may not be validated and its
methods may not be accepted by the scientific community;
difficulties enrolling patients in the Company's clinical trials;
the ability to timely source adequate supply of FasL; risks
resulting from unforeseen side effects; the Company's ability to
establish and maintain strategic partnerships and other corporate
collaborations; the scope of protection the Company is able to
establish and maintain for intellectual property rights and its
ability to operate its business without infringing the intellectual
property rights of others; competitive companies, technologies and
the Company's industry; unforeseen scientific difficulties may
develop with the Company's technology; and the Company's ability to
retain or attract key employees whose knowledge is essential to the
development of its products.. Any forward-looking statement in this
press release speaks only as of the date of this press release. The
Company undertakes no obligation to publicly update or review any
forward-looking statement, whether as a result of new information,
future developments or otherwise, except as may be required by any
applicable securities laws. More detailed information about the
risks and uncertainties affecting the Company is contained under
the heading "Risk Factors" in the Company's Annual Report on Form
20-F for the fiscal year ended December 31,
2017 filed with the U.S. Securities and Exchange Commission
("SEC"), which is available on the SEC's website,
http://www.sec.gov, and in the Company's periodic filings with the
SEC.
Contact:
Cellect Biotechnology Ltd.
Eyal Leibovitz, Chief Financial
Officer
http://www.cellect.co
+972-9-974-1444
View original
content:http://www.prnewswire.com/news-releases/cellect-to-present-its-breakthrough-stem-cell-production-technology-at-the-bio-europe-300742035.html
SOURCE Cellect Biotechnology Ltd.